Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T‐cell (CART) treatment is yet to be optimized. This study aims to investigate the safety and efficacy of sequential infusion of CD19‐CART and B‐cell...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Med
Autori principali: Yan, Lingzhi, Qu, Su, Shang, Jingjing, Shi, Xiaolan, Kang, Liqing, Xu, Nan, Zhu, Mingqing, Zhou, Jin, Jin, Song, Yao, Weiqin, Yao, Ying, Chen, Guanghua, Chang, Huirong, Zhu, Xiaming, Yu, Lei, Wu, Depei, Fu, Chengcheng
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Clinical Cancer Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7877347/
https://ncbi.nlm.nih.gov/pubmed/33356013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3624
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi